Dehu Dou

Nanjing, 211800, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Correction to "Pharmacokinetics, Biodistribution, Immunogenicity, and Model-Informed-Based PK/PD Model of a Next-Generation Advanced Novel Gene Therapy for Hemophilia".

Correction to "Pharmacokinetics, Biodistribution, Immunogenicity, and Model-Informed-Based PK/PD Model of a Next-Generation Advanced Novel Gene Therapy for Hemophilia".

Journal: Molecular pharmaceutics

Published: June 09, 2026

Correction: Preclinical Evaluation of AAV8-R338L Gene Therapy for Hemophilia: Efficacy, Pharmacokinetics, Distribution, Excretion and Toxicity in Mouse Models and Non-human Primates.

Correction: Preclinical Evaluation of AAV8-R338L Gene Therapy for Hemophilia: Efficacy, Pharmacokinetics, Distribution, Excretion and Toxicity in Mouse Models and Non-human Primates.

Journal: Pharmaceutical research

Published: May 28, 2026

Corrigendum to "Global regulatory considerations and practice for tumorigenicity evaluation of cell-based therapy" [2025 Feb;156:105769].

Corrigendum to "Global regulatory considerations and practice for tumorigenicity evaluation of cell-based therapy" [2025 Feb;156:105769].

Journal: Regulatory toxicology and pharmacology : RTP

Published: April 28, 2026

Pharmacokinetics, Biodistribution, Immunogenicity, and Model-Informed-Based PK/PD Model of a Next-Generation Advanced Novel Gene Therapy for Hemophilia.

Pharmacokinetics, Biodistribution, Immunogenicity, and Model-Informed-Based PK/PD Model of a Next-Generation Advanced Novel Gene Therapy for Hemophilia.

Journal: Molecular pharmaceutics

Published: September 17, 2025

Key Challenges and Optimization Practices for Non-clinical Evaluation of AAV based Gene Therapy for Central Nervous System Disease.

Key Challenges and Optimization Practices for Non-clinical Evaluation of AAV based Gene Therapy for Central Nervous System Disease.

Journal: Pharmaceutical research

Published: July 30, 2025

Preclinical Evaluation of AAV8-R338L Gene Therapy for Hemophilia: Efficacy, Pharmacokinetics, Distribution, Excretion and Toxicity in Mouse Models and Non-human Primates.

Preclinical Evaluation of AAV8-R338L Gene Therapy for Hemophilia: Efficacy, Pharmacokinetics, Distribution, Excretion and Toxicity in Mouse Models and Non-human Primates.

Journal: Pharmaceutical research

Published: June 15, 2025

Nonclinical absorption, distribution, metabolism, excretion and biomarkers properties of a modified N-acetylgalactosamine-conjugated small-interfering RNA for hypercholesteremia.

Nonclinical absorption, distribution, metabolism, excretion and biomarkers properties of a modified N-acetylgalactosamine-conjugated small-interfering RNA for hypercholesteremia.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: June 01, 2025

Off-target effects of oligonucleotides and approaches of preclinical assessments.

Off-target effects of oligonucleotides and approaches of preclinical assessments.

Journal: SLAS discovery : advancing life sciences R & D

Published: May 23, 2025

Enhanced pre- and postnatal developmental toxicity (ePPND) study in non-human primates: Necessity, strategic approaches, and critical considerations.

Enhanced pre- and postnatal developmental toxicity (ePPND) study in non-human primates: Necessity, strategic approaches, and critical considerations.

Journal: Regulatory toxicology and pharmacology : RTP

Published: December 01, 2024

Global regulatory considerations and practices for tumorigenicity evaluation of cell-based therapy.

Global regulatory considerations and practices for tumorigenicity evaluation of cell-based therapy.

Journal: Regulatory toxicology and pharmacology : RTP

Published: June 13, 2024

Showing 1-10 of 10

Last Updated: 09/26/2026